Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy

Cytotherapy

Volumn 18, Issue 8, 2016, Pages 1002-1011

  Mock, Ulrike ^a   Nickolay, Lauren ^a   Philip, Brian ^b   Cheung, Gordon Weng Kit ^b   Zhan, Hong ^a   Johnston, Ian C D ^c   Kaiser, Andrew D ^c   Peggs, Karl ^b   Pule, Martin ^b   Thrasher, Adrian J ^a   Qasim, Waseem ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MILTENYI BIOTEC GMBH   (Germany)

Author keywords

automation; CAR19; chimeric antigen receptors; CliniMACS prodigy; GMP; immunotherapy; T cells; T cell transduction

Indexed keywords

CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; LENTIVIRUS VECTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ARTICLE; AUTOMATION; B LYMPHOCYTE; CELL ENGINEERING; CELL EXPANSION; CONTROLLED STUDY; DONOR; HUMAN; HUMAN CELL; KINETICS; LEUKAPHERESIS; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; CELL SEPARATION; CHEMISTRY; COMPUTER AIDED DESIGN; DEVICES; DRUG SCREENING; EVALUATION STUDY; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; LABORATORY AUTOMATION; METABOLISM; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE;

ANIMALS; ANTIGENS, CD19; AUTOMATION, LABORATORY; B-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL ENGINEERING; CELL PROLIFERATION; CELL SEPARATION; CELLS, CULTURED; COMPUTER-AIDED DESIGN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84991821264     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.05.009     Document Type: Article

References (18)

1. [1] Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med, 3(95), 2011, 95ra73.
2. [2] Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. NEJM 371:16 (2014), 1507–1517.
3. [3] Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P.T., Carpenter, R.O., Stetler-Stevenson, M., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:6 (2015), 540–549.
4. [4] Kaiser, A.D., Assenmacher, M., Schroder, B., Meyer, M., Orentas, R., Bethke, U., et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther 22:2 (2015), 72–78.
5. [5] Zhan, H., Gilmour, K., Chan, L., Farzaneh, F., McNicol, A.M., Xu, J.H., et al. Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene. PLoS ONE, 8(10), 2013 e77106.
6. [6] Bajgain, P., Mucharla, R., Wilson, J., Welch, D., Anurathapan, U., Liang, B., et al. Optimizing the production of suspension cells using the G-Rex “M” series. Mol Ther Methods Clin Dev, 1, 2014, 14015.
7. [7] Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 32:2 (2009), 169–180.
8. [8] Apel, M., Brüning, M., Granzin, M., Essl, M., Stuth, J., Blaschke, J., et al. Integrated clinical scale manufacturing system for cellular products derived by magnetic cell separation, centrifugation and cell culture. Chem Ing Tech 85:1–2 (2013), 103–110.
9. [9] Spohn, G., Wiercinska, E., Karpova, D., Bunos, M., Hummer, C., Wingenfeld, E., et al. Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. Cytotherapy 17:10 (2015), 1465–1471.
10. [10] Granzin, M., Soltenborn, S., Muller, S., Kollet, J., Berg, M., Cerwenka, A., et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy 17:5 (2015), 621–632.
11. [11] Bunos, M., Hummer, C., Wingenfeld, E., Sorg, N., Pfirrmann, V., Bader, P., et al. Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise. Vox Sang 109:4 (2015), 387–393.
12. [12] Di, W.L., Mellerio, J.E., Bernadis, C., Harper, J., Abdul-Wahab, A., Ghani, S., et al. Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome. Hum Gene Ther Clin Dev 24:4 (2013), 182–190.
13. [13] Casati, A., Varghaei-Nahvi, A., Feldman, S.A., Assenmacher, M., Rosenberg, S.A., Dudley, M.E., et al. Clinical-scale selection and viral transduction of human naive and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother 62:10 (2013), 1563–1573.
14. [14] Blank, C., Mackensen, A., Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56:5 (2007), 739–745.
15. [15] Gattinoni, L., Powell, D.J. Jr, Rosenberg, S.A., Restifo, N.P., Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6:5 (2006), 383–393.
16. [16] Nishimura, T., Nakui, M., Sato, M., Iwakabe, K., Kitamura, H., Sekimoto, M., et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 46:Suppl. (2000), S52–61.
17. [17] Flynn, J.K., Gorry, P.R., Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies. Clin Transl Immunol, 3(7), 2014, e20.
18. [18] Berger, C., Jensen, M.C., Lansdorp, P.M., Gough, M., Elliott, C., Riddell, S.R., Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118:1 (2008), 294–305.